Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $7.00 at Royal Bank of Canada

Health Catalyst (NASDAQ:HCATGet Free Report) had its price target decreased by Royal Bank of Canada from $9.00 to $7.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 21.95% from the company’s previous close.

HCAT has been the subject of several other reports. Evercore ISI lifted their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Citigroup lowered their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Stephens upped their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $11.27.

View Our Latest Stock Analysis on HCAT

Health Catalyst Stock Down 2.7 %

NASDAQ:HCAT traded down $0.16 during mid-day trading on Wednesday, hitting $5.74. 37,971 shares of the company’s stock traded hands, compared to its average volume of 565,028. The company has a fifty day moving average of $7.73 and a 200 day moving average of $7.54. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.06. The company has a market capitalization of $349.27 million, a P/E ratio of -4.25 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCATGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the company posted ($0.22) earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts forecast that Health Catalyst will post -0.33 EPS for the current year.

Insider Transactions at Health Catalyst

In related news, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the transaction, the general counsel now owns 72,250 shares in the company, valued at $601,120. This represents a 21.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,727 shares of company stock valued at $601,810 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Primecap Management Co. CA raised its holdings in Health Catalyst by 14.7% in the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after acquiring an additional 305,079 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at about $897,000. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $6,858,000. Millrace Asset Group Inc. acquired a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $1,568,000. Finally, Point72 Asset Management L.P. increased its holdings in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

(Get Free Report)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Read More

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.